Publication:
The change in plasma GABA, glutamine and glutamate levels in fluoxetine- or S-citalopram-treated female patients with major depression

dc.contributor.authorGÖREN, MEHMET ZAFER
dc.contributor.authorsKucukibrahimoglu, Esra; Saygin, Melek Z.; Caliskan, Mecit; Kaplan, Okan K.; Unsal, Cuneyt; Goren, M. Zafer
dc.date.accessioned2022-03-12T17:38:11Z
dc.date.accessioned2026-01-10T16:55:40Z
dc.date.available2022-03-12T17:38:11Z
dc.date.issued2009
dc.description.abstractObjective The aim of this study was to investigate the relationship between plasma glutamate, glutamine and gamma-aminobutyric acid (GABA) levels in female patients with major depression treated with S-citalopram or fluoxetine. Methods The patients were assigned into S-citalopram (10 mg/day) or fluoxetine (20 mg/day) groups (n= 15 per group). The Hamilton and Beck Depression Inventory Scales were performed on all study participants, and blood samples were collected. The same procedures were repeated 10 days following the onset of therapy. Fifteen female healthy volunteers were also included in the study for the evaluation of normal plasma levels. Results The plasma GABA levels of the healthy volunteers were higher whereas those for glutamate and glutamine were lower than the day zero samples of the patients. An increase in plasma GABA levels and a decrease in glutamate and glutamine levels were observed on the 10th day of treatment. No difference was detected between the drug treatments. Conclusion Our findings may suggest that GABA, glutamate and glutamine play a role in depression and that plasma GABA may be used as a biomarker for treatment control.
dc.identifier.doi10.1007/s00228-009-0650-7
dc.identifier.eissn1432-1041
dc.identifier.issn0031-6970
dc.identifier.pubmed19373461
dc.identifier.urihttps://hdl.handle.net/11424/229457
dc.identifier.wosWOS:000266886000004
dc.language.isoeng
dc.publisherSPRINGER HEIDELBERG
dc.relation.ispartofEUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.subjectAntidepressant therapy
dc.subjectBiomarker
dc.subjectSSRI
dc.subjectTherapy control
dc.subjectGAMMA-AMINOBUTYRIC-ACID
dc.subjectPERFORMANCE LIQUID-CHROMATOGRAPHY
dc.subjectRAT CEREBRAL-CORTEX
dc.subjectMOOD DISORDERS
dc.subjectELECTROCONVULSIVE-THERAPY
dc.subjectSULFITE DERIVATIZATION
dc.subjectPREFRONTAL CORTEX
dc.subjectRECEPTOR CHANNELS
dc.subjectCINGULATE CORTEX
dc.subjectRAPHE NUCLEI
dc.titleThe change in plasma GABA, glutamine and glutamate levels in fluoxetine- or S-citalopram-treated female patients with major depression
dc.typearticle
dspace.entity.typePublication
oaire.citation.endPage577
oaire.citation.issue6
oaire.citation.startPage571
oaire.citation.titleEUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
oaire.citation.volume65

Files